Guardant Health, Inc. (GH) Stock Competitors & Peer Comparison
See (GH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GH | $162.96 | +1.78% | 21.6B | -63.16 | -$2.58 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.71% |
| TMO | $535.29 | +0.23% | 198.9B | 23.11 | $23.16 | +0.33% |
| DHR | $200.79 | +0.87% | 142.1B | 25.16 | $7.98 | +0.71% |
| IDXX | $557.02 | +3.02% | 43.9B | 41.02 | $13.58 | N/A |
| NTRA | $277.37 | +1.73% | 39.7B | -174.45 | -$1.59 | N/A |
| A | $134.71 | -0.36% | 38B | 23.18 | $5.81 | +0.75% |
| IQV | $206.81 | -0.49% | 34.5B | 17.06 | $12.13 | N/A |
| ILMN | $187.15 | -2.12% | 28.3B | 37.21 | $5.03 | N/A |
| MTD | $1,316.55 | +0.13% | 26.6B | 30.25 | $43.51 | N/A |
Stock Comparison
GH vs DHR-PB Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, GH is priced at $162.96, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, GH's ROE is +1.84%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, GH is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check DHR-PB's competition here
GH vs TMO Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, TMO has a market cap of 198.9B. Regarding current trading prices, GH is priced at $162.96, while TMO trades at $535.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas TMO's P/E ratio is 23.11. In terms of profitability, GH's ROE is +1.84%, compared to TMO's ROE of +0.13%. Regarding short-term risk, GH is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check TMO's competition here
GH vs DHR Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, DHR has a market cap of 142.1B. Regarding current trading prices, GH is priced at $162.96, while DHR trades at $200.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas DHR's P/E ratio is 25.16. In terms of profitability, GH's ROE is +1.84%, compared to DHR's ROE of +0.07%. Regarding short-term risk, GH is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check DHR's competition here
GH vs IDXX Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, IDXX has a market cap of 43.9B. Regarding current trading prices, GH is priced at $162.96, while IDXX trades at $557.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas IDXX's P/E ratio is 41.02. In terms of profitability, GH's ROE is +1.84%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, GH is less volatile compared to IDXX. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check IDXX's competition here
GH vs NTRA Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, NTRA has a market cap of 39.7B. Regarding current trading prices, GH is priced at $162.96, while NTRA trades at $277.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas NTRA's P/E ratio is -174.45. In terms of profitability, GH's ROE is +1.84%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, GH is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NTRA's competition here
GH vs A Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, A has a market cap of 38B. Regarding current trading prices, GH is priced at $162.96, while A trades at $134.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas A's P/E ratio is 23.18. In terms of profitability, GH's ROE is +1.84%, compared to A's ROE of +0.21%. Regarding short-term risk, GH is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check A's competition here
GH vs IQV Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, IQV has a market cap of 34.5B. Regarding current trading prices, GH is priced at $162.96, while IQV trades at $206.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas IQV's P/E ratio is 17.06. In terms of profitability, GH's ROE is +1.84%, compared to IQV's ROE of +0.22%. Regarding short-term risk, GH is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check IQV's competition here
GH vs ILMN Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, ILMN has a market cap of 28.3B. Regarding current trading prices, GH is priced at $162.96, while ILMN trades at $187.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas ILMN's P/E ratio is 37.21. In terms of profitability, GH's ROE is +1.84%, compared to ILMN's ROE of +0.34%. Regarding short-term risk, GH is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ILMN's competition here
GH vs MTD Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, MTD has a market cap of 26.6B. Regarding current trading prices, GH is priced at $162.96, while MTD trades at $1,316.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas MTD's P/E ratio is 30.25. In terms of profitability, GH's ROE is +1.84%, compared to MTD's ROE of -6.10%. Regarding short-term risk, GH is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check MTD's competition here
GH vs WAT Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, WAT has a market cap of 24.4B. Regarding current trading prices, GH is priced at $162.96, while WAT trades at $374.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas WAT's P/E ratio is 27.61. In terms of profitability, GH's ROE is +1.84%, compared to WAT's ROE of +0.08%. Regarding short-term risk, GH is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check WAT's competition here
GH vs DGX Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, DGX has a market cap of 22.3B. Regarding current trading prices, GH is priced at $162.96, while DGX trades at $201.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas DGX's P/E ratio is 19.91. In terms of profitability, GH's ROE is +1.84%, compared to DGX's ROE of +0.14%. Regarding short-term risk, GH is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check DGX's competition here
GH vs LH Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, LH has a market cap of 22.3B. Regarding current trading prices, GH is priced at $162.96, while LH trades at $271.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas LH's P/E ratio is 16.14. In terms of profitability, GH's ROE is +1.84%, compared to LH's ROE of +0.11%. Regarding short-term risk, GH is more volatile compared to LH. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check LH's competition here
GH vs EXAS Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, GH is priced at $162.96, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas EXAS's P/E ratio is -95.37. In terms of profitability, GH's ROE is +1.84%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, GH is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check EXAS's competition here
GH vs ILMNV Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, GH is priced at $162.96, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas ILMNV's P/E ratio is N/A. In terms of profitability, GH's ROE is +1.84%, compared to ILMNV's ROE of N/A. Regarding short-term risk, GH is more volatile compared to ILMNV. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check ILMNV's competition here
GH vs MEDP Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, MEDP has a market cap of 15.1B. Regarding current trading prices, GH is priced at $162.96, while MEDP trades at $529.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas MEDP's P/E ratio is 33.26. In terms of profitability, GH's ROE is +1.84%, compared to MEDP's ROE of +1.21%. Regarding short-term risk, GH is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check MEDP's competition here
GH vs PKI Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, GH is priced at $162.96, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas PKI's P/E ratio is 41.45. In terms of profitability, GH's ROE is +1.84%, compared to PKI's ROE of +0.03%. Regarding short-term risk, GH is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check PKI's competition here
GH vs ICLR Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, GH is priced at $162.96, while ICLR trades at $172.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas ICLR's P/E ratio is 14.04. In terms of profitability, GH's ROE is +1.84%, compared to ICLR's ROE of +0.05%. Regarding short-term risk, GH is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ICLR's competition here
GH vs RVTY Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, RVTY has a market cap of 12.4B. Regarding current trading prices, GH is priced at $162.96, while RVTY trades at $111.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas RVTY's P/E ratio is 21.74. In terms of profitability, GH's ROE is +1.84%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, GH is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check RVTY's competition here
GH vs CRL Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, CRL has a market cap of 11B. Regarding current trading prices, GH is priced at $162.96, while CRL trades at $228.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas CRL's P/E ratio is 22.82. In terms of profitability, GH's ROE is +1.84%, compared to CRL's ROE of -0.06%. Regarding short-term risk, GH is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CRL's competition here
GH vs QGEN Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, QGEN has a market cap of 8.5B. Regarding current trading prices, GH is priced at $162.96, while QGEN trades at $41.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas QGEN's P/E ratio is 17.25. In terms of profitability, GH's ROE is +1.84%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, GH is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check QGEN's competition here
GH vs BLLN Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, BLLN has a market cap of 6B. Regarding current trading prices, GH is priced at $162.96, while BLLN trades at $129.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas BLLN's P/E ratio is 236.15. In terms of profitability, GH's ROE is +1.84%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, GH is less volatile compared to BLLN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BLLN's competition here
GH vs TWST Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, TWST has a market cap of 5.8B. Regarding current trading prices, GH is priced at $162.96, while TWST trades at $92.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas TWST's P/E ratio is -45.40. In terms of profitability, GH's ROE is +1.84%, compared to TWST's ROE of -0.17%. Regarding short-term risk, GH is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check TWST's competition here
GH vs SHC Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, GH is priced at $162.96, while SHC trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas SHC's P/E ratio is 20.17. In terms of profitability, GH's ROE is +1.84%, compared to SHC's ROE of +0.21%. Regarding short-term risk, GH is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check SHC's competition here
GH vs RDNT Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, RDNT has a market cap of 4.8B. Regarding current trading prices, GH is priced at $162.96, while RDNT trades at $61.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas RDNT's P/E ratio is 133.50. In terms of profitability, GH's ROE is +1.84%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, GH is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check RDNT's competition here
GH vs VCYT Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, VCYT has a market cap of 4.7B. Regarding current trading prices, GH is priced at $162.96, while VCYT trades at $59.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas VCYT's P/E ratio is 29.76. In terms of profitability, GH's ROE is +1.84%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, GH is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check VCYT's competition here
GH vs SYNH Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, GH is priced at $162.96, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas SYNH's P/E ratio is 61.40. In terms of profitability, GH's ROE is +1.84%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, GH is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check SYNH's competition here
GH vs OLK Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, GH is priced at $162.96, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas OLK's P/E ratio is -96.59. In terms of profitability, GH's ROE is +1.84%, compared to OLK's ROE of -0.07%. Regarding short-term risk, GH is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check OLK's competition here
GH vs NEOG Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, NEOG has a market cap of 2.2B. Regarding current trading prices, GH is priced at $162.96, while NEOG trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas NEOG's P/E ratio is 35.64. In terms of profitability, GH's ROE is +1.84%, compared to NEOG's ROE of -0.29%. Regarding short-term risk, GH is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NEOG's competition here
GH vs CDNA Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, CDNA has a market cap of 1.5B. Regarding current trading prices, GH is priced at $162.96, while CDNA trades at $29.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas CDNA's P/E ratio is 35.42. In terms of profitability, GH's ROE is +1.84%, compared to CDNA's ROE of -0.03%. Regarding short-term risk, GH is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CDNA's competition here
GH vs PSNL Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, PSNL has a market cap of 1.4B. Regarding current trading prices, GH is priced at $162.96, while PSNL trades at $15.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas PSNL's P/E ratio is -15.48. In terms of profitability, GH's ROE is +1.84%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, GH is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check PSNL's competition here
GH vs CSTL Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, CSTL has a market cap of 728.5M. Regarding current trading prices, GH is priced at $162.96, while CSTL trades at $24.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas CSTL's P/E ratio is -54.59. In terms of profitability, GH's ROE is +1.84%, compared to CSTL's ROE of -0.03%. Regarding short-term risk, GH is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CSTL's competition here
GH vs FLGT Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, FLGT has a market cap of 596.7M. Regarding current trading prices, GH is priced at $162.96, while FLGT trades at $21.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas FLGT's P/E ratio is 2101.00. In terms of profitability, GH's ROE is +1.84%, compared to FLGT's ROE of -0.07%. Regarding short-term risk, GH is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check FLGT's competition here
GH vs MYGN Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, MYGN has a market cap of 596M. Regarding current trading prices, GH is priced at $162.96, while MYGN trades at $6.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas MYGN's P/E ratio is -48.54. In terms of profitability, GH's ROE is +1.84%, compared to MYGN's ROE of -1.09%. Regarding short-term risk, GH is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MYGN's competition here
GH vs GRALV Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, GH is priced at $162.96, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas GRALV's P/E ratio is N/A. In terms of profitability, GH's ROE is +1.84%, compared to GRALV's ROE of N/A. Regarding short-term risk, GH is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check GRALV's competition here
GH vs CO Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, GH is priced at $162.96, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas CO's P/E ratio is 5.06. In terms of profitability, GH's ROE is +1.84%, compared to CO's ROE of +0.11%. Regarding short-term risk, GH is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CO's competition here
GH vs NEO Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, NEO has a market cap of 377.6M. Regarding current trading prices, GH is priced at $162.96, while NEO trades at $14.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas NEO's P/E ratio is 111.54. In terms of profitability, GH's ROE is +1.84%, compared to NEO's ROE of -0.12%. Regarding short-term risk, GH is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NEO's competition here
GH vs PRENW Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, PRENW has a market cap of 369.5M. Regarding current trading prices, GH is priced at $162.96, while PRENW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas PRENW's P/E ratio is N/A. In terms of profitability, GH's ROE is +1.84%, compared to PRENW's ROE of -0.47%. Regarding short-term risk, GH is more volatile compared to PRENW. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check PRENW's competition here
GH vs PRE Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, PRE has a market cap of 332.9M. Regarding current trading prices, GH is priced at $162.96, while PRE trades at $19.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas PRE's P/E ratio is -9.50. In terms of profitability, GH's ROE is +1.84%, compared to PRE's ROE of -0.47%. Regarding short-term risk, GH is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check PRE's competition here
GH vs FLDM Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, GH is priced at $162.96, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas FLDM's P/E ratio is -4.74. In terms of profitability, GH's ROE is +1.84%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, GH is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check FLDM's competition here
GH vs BDSX Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, BDSX has a market cap of 170.9M. Regarding current trading prices, GH is priced at $162.96, while BDSX trades at $21.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas BDSX's P/E ratio is -5.17. In terms of profitability, GH's ROE is +1.84%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, GH is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BDSX's competition here
GH vs IMDX Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, IMDX has a market cap of 129.4M. Regarding current trading prices, GH is priced at $162.96, while IMDX trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas IMDX's P/E ratio is -4.05. In terms of profitability, GH's ROE is +1.84%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, GH is less volatile compared to IMDX. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check IMDX's competition here
GH vs STIM Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, STIM has a market cap of 128M. Regarding current trading prices, GH is priced at $162.96, while STIM trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas STIM's P/E ratio is -3.41. In terms of profitability, GH's ROE is +1.84%, compared to STIM's ROE of -1.65%. Regarding short-term risk, GH is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check STIM's competition here
GH vs GTH Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, GH is priced at $162.96, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas GTH's P/E ratio is -1.11. In terms of profitability, GH's ROE is +1.84%, compared to GTH's ROE of -1.01%. Regarding short-term risk, GH is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check GTH's competition here
GH vs GENE Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, GH is priced at $162.96, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas GENE's P/E ratio is -38.25. In terms of profitability, GH's ROE is +1.84%, compared to GENE's ROE of -1.85%. Regarding short-term risk, GH is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check GENE's competition here
GH vs XGN Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, XGN has a market cap of 103.9M. Regarding current trading prices, GH is priced at $162.96, while XGN trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas XGN's P/E ratio is -5.81. In terms of profitability, GH's ROE is +1.84%, compared to XGN's ROE of -1.14%. Regarding short-term risk, GH is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check XGN's competition here
GH vs SERA Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, SERA has a market cap of 82.5M. Regarding current trading prices, GH is priced at $162.96, while SERA trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas SERA's P/E ratio is -3.32. In terms of profitability, GH's ROE is +1.84%, compared to SERA's ROE of -0.41%. Regarding short-term risk, GH is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check SERA's competition here
GH vs ATLN Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, GH is priced at $162.96, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas ATLN's P/E ratio is -0.68. In terms of profitability, GH's ROE is +1.84%, compared to ATLN's ROE of +14.94%. Regarding short-term risk, GH is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ATLN's competition here
GH vs DRIO Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, DRIO has a market cap of 49.4M. Regarding current trading prices, GH is priced at $162.96, while DRIO trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas DRIO's P/E ratio is -1.15. In terms of profitability, GH's ROE is +1.84%, compared to DRIO's ROE of +0.93%. Regarding short-term risk, GH is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check DRIO's competition here
GH vs PRPO Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, PRPO has a market cap of 45.1M. Regarding current trading prices, GH is priced at $162.96, while PRPO trades at $25.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas PRPO's P/E ratio is -97.08. In terms of profitability, GH's ROE is +1.84%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, GH is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check PRPO's competition here
GH vs STRR Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, STRR has a market cap of 42.9M. Regarding current trading prices, GH is priced at $162.96, while STRR trades at $11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas STRR's P/E ratio is -12.21. In terms of profitability, GH's ROE is +1.84%, compared to STRR's ROE of -0.14%. Regarding short-term risk, GH is more volatile compared to STRR. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check STRR's competition here
GH vs STRRP Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, STRRP has a market cap of 40.7M. Regarding current trading prices, GH is priced at $162.96, while STRRP trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas STRRP's P/E ratio is -18.61. In terms of profitability, GH's ROE is +1.84%, compared to STRRP's ROE of -0.14%. Regarding short-term risk, GH is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check STRRP's competition here
GH vs AKU Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, GH is priced at $162.96, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas AKU's P/E ratio is -0.13. In terms of profitability, GH's ROE is +1.84%, compared to AKU's ROE of -5.32%. Regarding short-term risk, GH is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check AKU's competition here
GH vs MDXH Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, MDXH has a market cap of 22.9M. Regarding current trading prices, GH is priced at $162.96, while MDXH trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas MDXH's P/E ratio is -1.17. In terms of profitability, GH's ROE is +1.84%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, GH is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MDXH's competition here
GH vs CEMI Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, GH is priced at $162.96, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas CEMI's P/E ratio is -0.63. In terms of profitability, GH's ROE is +1.84%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, GH is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check CEMI's competition here
GH vs ENZ Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, GH is priced at $162.96, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas ENZ's P/E ratio is -2.24. In terms of profitability, GH's ROE is +1.84%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, GH is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ENZ's competition here
GH vs QUCY Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, QUCY has a market cap of 15.6M. Regarding current trading prices, GH is priced at $162.96, while QUCY trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas QUCY's P/E ratio is -0.06. In terms of profitability, GH's ROE is +1.84%, compared to QUCY's ROE of -3.26%. Regarding short-term risk, GH is less volatile compared to QUCY. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check QUCY's competition here
GH vs PMD Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, GH is priced at $162.96, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas PMD's P/E ratio is -5.24. In terms of profitability, GH's ROE is +1.84%, compared to PMD's ROE of -0.32%. Regarding short-term risk, GH is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check PMD's competition here
GH vs ME Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, GH is priced at $162.96, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas ME's P/E ratio is -0.03. In terms of profitability, GH's ROE is +1.84%, compared to ME's ROE of -42.03%. Regarding short-term risk, GH is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check ME's competition here
GH vs MYNZ Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, GH is priced at $162.96, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, GH's ROE is +1.84%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, GH is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MYNZ's competition here
GH vs BNGO Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, BNGO has a market cap of 13.7M. Regarding current trading prices, GH is priced at $162.96, while BNGO trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas BNGO's P/E ratio is -0.27. In terms of profitability, GH's ROE is +1.84%, compared to BNGO's ROE of -0.71%. Regarding short-term risk, GH is more volatile compared to BNGO. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check BNGO's competition here
GH vs CHEK Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, GH is priced at $162.96, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas CHEK's P/E ratio is -0.43. In terms of profitability, GH's ROE is +1.84%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, GH is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CHEK's competition here
GH vs BNR Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, BNR has a market cap of 10.3M. Regarding current trading prices, GH is priced at $162.96, while BNR trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas BNR's P/E ratio is -11.84. In terms of profitability, GH's ROE is +1.84%, compared to BNR's ROE of -0.11%. Regarding short-term risk, GH is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BNR's competition here
GH vs CNTG Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, GH is priced at $162.96, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas CNTG's P/E ratio is -0.23. In terms of profitability, GH's ROE is +1.84%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, GH is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check CNTG's competition here
GH vs APDN Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, GH is priced at $162.96, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas APDN's P/E ratio is -0.10. In terms of profitability, GH's ROE is +1.84%, compared to APDN's ROE of -6.53%. Regarding short-term risk, GH is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check APDN's competition here
GH vs MBAI Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, MBAI has a market cap of 5.9M. Regarding current trading prices, GH is priced at $162.96, while MBAI trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas MBAI's P/E ratio is 1.51. In terms of profitability, GH's ROE is +1.84%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, GH is less volatile compared to MBAI. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MBAI's competition here
GH vs NVTA Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, GH is priced at $162.96, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas NVTA's P/E ratio is -0.00. In terms of profitability, GH's ROE is +1.84%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, GH is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NVTA's competition here
GH vs ADVB Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, ADVB has a market cap of 5.4M. Regarding current trading prices, GH is priced at $162.96, while ADVB trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas ADVB's P/E ratio is -45.45. In terms of profitability, GH's ROE is +1.84%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, GH is more volatile compared to ADVB. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check ADVB's competition here
GH vs LMDXW Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, GH is priced at $162.96, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, GH's ROE is +1.84%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, GH is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check LMDXW's competition here
GH vs LMDX Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, GH is priced at $162.96, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas LMDX's P/E ratio is -0.01. In terms of profitability, GH's ROE is +1.84%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, GH is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check LMDX's competition here
GH vs NDRA Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, NDRA has a market cap of 4.2M. Regarding current trading prices, GH is priced at $162.96, while NDRA trades at $5.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas NDRA's P/E ratio is -0.72. In terms of profitability, GH's ROE is +1.84%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, GH is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NDRA's competition here
GH vs TRIB Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, TRIB has a market cap of 3.7M. Regarding current trading prices, GH is priced at $162.96, while TRIB trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas TRIB's P/E ratio is -0.09. In terms of profitability, GH's ROE is +1.84%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, GH is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check TRIB's competition here
GH vs DMTK Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, GH is priced at $162.96, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas DMTK's P/E ratio is -0.04. In terms of profitability, GH's ROE is +1.84%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, GH is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check DMTK's competition here
GH vs BIAF Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, BIAF has a market cap of 3.3M. Regarding current trading prices, GH is priced at $162.96, while BIAF trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas BIAF's P/E ratio is -0.08. In terms of profitability, GH's ROE is +1.84%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, GH is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BIAF's competition here
GH vs NOTV Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, GH is priced at $162.96, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas NOTV's P/E ratio is -0.03. In terms of profitability, GH's ROE is +1.84%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, GH is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NOTV's competition here
GH vs SQL Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, GH is priced at $162.96, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas SQL's P/E ratio is -0.40. In terms of profitability, GH's ROE is +1.84%, compared to SQL's ROE of +38.02%. Regarding short-term risk, GH is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check SQL's competition here
GH vs AWH Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, GH is priced at $162.96, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas AWH's P/E ratio is -0.09. In terms of profitability, GH's ROE is +1.84%, compared to AWH's ROE of +2.03%. Regarding short-term risk, GH is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check AWH's competition here
GH vs INBS Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, INBS has a market cap of 1.5M. Regarding current trading prices, GH is priced at $162.96, while INBS trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas INBS's P/E ratio is -0.27. In terms of profitability, GH's ROE is +1.84%, compared to INBS's ROE of -1.74%. Regarding short-term risk, GH is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check INBS's competition here
GH vs HTGM Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, GH is priced at $162.96, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas HTGM's P/E ratio is -0.03. In terms of profitability, GH's ROE is +1.84%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, GH is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check HTGM's competition here
GH vs BIOC Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, GH is priced at $162.96, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas BIOC's P/E ratio is -0.01. In terms of profitability, GH's ROE is +1.84%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, GH is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BIOC's competition here
GH vs ISPC Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, ISPC has a market cap of 309.7K. Regarding current trading prices, GH is priced at $162.96, while ISPC trades at $2.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas ISPC's P/E ratio is -0.07. In terms of profitability, GH's ROE is +1.84%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, GH is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ISPC's competition here
GH vs SQLLW Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, GH is priced at $162.96, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, GH's ROE is +1.84%, compared to SQLLW's ROE of +38.02%. Regarding short-term risk, GH is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check SQLLW's competition here
GH vs CHEKZ Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, GH is priced at $162.96, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, GH's ROE is +1.84%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, GH is less volatile compared to CHEKZ. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CHEKZ's competition here
GH vs DHR-PA Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, GH is priced at $162.96, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, GH's ROE is +1.84%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, GH is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check DHR-PA's competition here
GH vs NDRAW Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, GH is priced at $162.96, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas NDRAW's P/E ratio is N/A. In terms of profitability, GH's ROE is +1.84%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, GH is less volatile compared to NDRAW. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NDRAW's competition here
GH vs OCDX Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, GH is priced at $162.96, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas OCDX's P/E ratio is -42.28. In terms of profitability, GH's ROE is +1.84%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, GH is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check OCDX's competition here
GH vs MEUSW Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, GH is priced at $162.96, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas MEUSW's P/E ratio is N/A. In terms of profitability, GH's ROE is +1.84%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, GH is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MEUSW's competition here
GH vs PRXL Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, GH is priced at $162.96, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas PRXL's P/E ratio is 43.49. In terms of profitability, GH's ROE is +1.84%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, GH is more volatile compared to PRXL. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check PRXL's competition here
GH vs BNGOW Comparison July 2026
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 21.6B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, GH is priced at $162.96, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -63.16, whereas BNGOW's P/E ratio is N/A. In terms of profitability, GH's ROE is +1.84%, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, GH is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BNGOW's competition here